University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
J Crohns Colitis. 2022 May 11;16(Supplement_2):ii42-ii53. doi: 10.1093/ecco-jcc/jjac038.
Interleukin [IL]-23 is a member of the IL-12 family of cytokines and has been implicated in multiple inflammatory disorders including psoriasis, psoriatic arthritis, and the inflammatory bowel diseases [IBDs]. Blockade of both IL-12 and IL-23 using an antibody that targets a shared subunit is highly effective in treating psoriasis, and recent data suggest similar efficacy in IBD with minimal adverse events. In this review, we summarise published data on the efficacy of anti-IL-12/23 therapies in IBD as well as emerging data on more selective anti-IL-23 specific therapies. Last, we discuss novel therapeutics under development which target the IL-23 pathway in unique ways and suggest that a biomarker-driven approach will soon guide clinicians to prescribe anti-IL-23 therapies to the patients most likely to respond to them.
白细胞介素[IL]-23 是白细胞介素 12 家族细胞因子的成员，与多种炎症性疾病有关，包括银屑病、银屑病关节炎和炎症性肠病[IBD]。使用针对共同亚基的抗体阻断 IL-12 和 IL-23 在治疗银屑病方面非常有效，最近的数据表明在 IBD 中具有相似的疗效，且不良反应最小。在这篇综述中，我们总结了关于抗 IL-12/23 疗法在 IBD 中的疗效的已发表数据，以及关于更具选择性的抗 IL-23 特异性疗法的新数据。最后，我们讨论了正在开发的针对 IL-23 途径的新型治疗方法，并认为基于生物标志物的方法将很快指导临床医生为最有可能对其产生反应的患者开抗 IL-23 疗法。
Zotero 插件